CoChat

Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research

Open access

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index; 58 of the 197 sources its claims cite were checked for support.

Abstract

Although the study of cognitive disengagement syndrome (CDS; previously called sluggish cognitive tempo) first emerged in the 1980s, very little is known about treating CDS or its impact on evidence-based interventions for attention-deficit/hyperactivity disorder (ADHD) with which it frequently co-occurs. The objective of this leading article was to investigate the existing evidence on medication treatment and CDS, including studies that have examined CDS response to medication and CDS as a moderator of ADHD treatment response. A total of seven studies were identified. At present, the limited existing literature suggests that psychostimulants such as methylphenidate and lisdexamfetamine, as well as atomoxetine, may improve CDS symptoms, although replication and research on related medications is needed. However, there are indications that CDS symptoms may predict a reduced response to methylphenidate in children with ADHD. Although untested, research on the neurobiological, neuropsychological, and behavioral correlates of CDS point to a possible benefit of other ADHD medications (e.g., guanfacine), medications that treat narcolepsy (e.g., modafinil), and medications traditionally used to treat depression and anxiety (e.g., viloxazine, bupropion, fluvoxamine), some of which have also recently been used in ADHD management. The article concludes with recommendations for future research on pharmacologic treatment and CDS.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40263-023-00999-5

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

29 Valid · 0 Not valid · 51 Not checked · 12 Own results and interpretations

51 more claims · 17 with their cited sources checked

Create a free account to see all 92 claims and to verify the 139 references still open.

See all claims — free account
  • It may state two separate claims as one. 26
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 73 references

Research works printed but not linked: 3

  1. Kardaş B, Baytunca B, Bolat GÜ, et al. An investigation of cranial functional magnetic resonance imaging results in children and adolescents with attention deficit and hyperactivity disorder and sluggish cognitive tempo (SCT). Int J Child Health Hum Dev. 2021;14(1):21–33.
  2. Barkley RA. Barkley sluggish cognitive tempo scale-children and adolescents (BSCTS-CA). New York: Guilford; 2018.
  3. Achenbach TM, Edelbrock C. Child behavior checklist. Burlington (Vt). 1991;7:371–92.

Cited by

See all 18

Metadata

Authors
Wiggs, K. K., Froehlich, T. E., & Becker, S. P.
Affiliations
Cincinnati Children's Hospital Medical Center (US)
Corresponding author
Becker, Stephen P.
Venue
CNS Drugs
Published
2023-04
Volume
37
Issue
4
Pages
293-304
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
OpenAlex
W4365815190
Cited by
16
References
73
Citations by year
2026: 5 · 2025: 4 · 2024: 6 · 2023: 1
FWCI
3.26
Type
journal article
Language
en
Open access
Licence
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute of Mental Health (R01MH122415)
  • Institute of Education Sciences (R305A200028)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
  • Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
Keywords
cognitive disengagement syndrome, sluggish cognitive tempo, attention deficit hyperactivity disorder, methylphenidate, lisdexamfetamine, atomoxetine, guanfacine, modafinil, viloxazine, bupropion, fluvoxamine, treatment moderators, children
MeSH terms
Atomoxetine Hydrochloride, Lisdexamfetamine Dimesylate, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Cognition, Humans, Methylphenidate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research. https://app.cochat.ai/papers/10.1007/s40263-023-00999-5
The paper
Wiggs, K. K., Froehlich, T. E., & Becker, S. P. (2023). Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research. CNS Drugs. https://doi.org/10.1007/s40263-023-00999-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.